Horizons in the Pharmacotherapy of Obesity
Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT 2C agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The...
Gespeichert in:
| Veröffentlicht in: | Current obesity reports 2015-12, Vol.4 (4), p.451-459 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 4 |
| container_start_page | 451 |
| container_title | Current obesity reports |
| container_volume | 4 |
| creator | Arch, Jonathan R. S. |
| description | Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT
2C
agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators’ caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy. |
| doi_str_mv | 10.1007/s13679-015-0177-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1727993287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1727993287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-fe67690c026adb6a215862136da9c65af52da245c0a3b84e3ce550dd1baa0c093</originalsourceid><addsrcrecordid>eNp9kF9LwzAUxYMobsx9AF-kjyJU8z_Nowx1wmA-6HO4TVPXsTYzaR_mpzejKj4ZCDmQcw73_hC6JPiWYKzuImFS6RwTka5SOT9BU0okzbmWxekfPUHzGLc4HYmJZPQcTahkXDLNp-hm6UPz6buYNV3Wb1z2soHQgvVJB9gfMl9n69LFpj9coLMadtHNv98Zent8eF0s89X66Xlxv8otF6rPayeV1NhiKqEqJVAiCknTsBVoKwXUglZAubAYWFlwx6wTAlcVKQFSSrMZuh5798F_DC72pm2idbsddM4P0RBFldaMFipZyWi1wccYXG32oWkhHAzB5kjJjJRMomSOlAxPmavv-qFsXfWb-GGSDHQ0xPTVvbtgtn4IXVr5n9Yvu_RwvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1727993287</pqid></control><display><type>article</type><title>Horizons in the Pharmacotherapy of Obesity</title><source>MEDLINE</source><source>Springer Journals</source><creator>Arch, Jonathan R. S.</creator><creatorcontrib>Arch, Jonathan R. S.</creatorcontrib><description>Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT
2C
agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators’ caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.</description><identifier>ISSN: 2162-4968</identifier><identifier>EISSN: 2162-4968</identifier><identifier>DOI: 10.1007/s13679-015-0177-4</identifier><identifier>PMID: 26346394</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adipose Tissue, Brown - drug effects ; Adipose Tissue, Brown - metabolism ; Anti-Obesity Agents - pharmacology ; Anti-Obesity Agents - therapeutic use ; Appetite Depressants - therapeutic use ; Behavioral Therapy ; Benzazepines - therapeutic use ; Cardiology ; Cinnamates - therapeutic use ; Clinical Trials as Topic ; Cyclohexanes - therapeutic use ; Diabetes ; Drug Approval ; Drug Combinations ; Endocrinology ; Epoxy Compounds - therapeutic use ; Europe ; Humans ; Lactones - therapeutic use ; Liraglutide - therapeutic use ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Metabolism (P Trayhurn ; Molecular Targeted Therapy - trends ; Obesity - drug therapy ; Section Editor ; Sesquiterpenes - therapeutic use ; Thermogenesis - drug effects ; Topical Collection on Metabolism ; United States ; Weight Loss - drug effects</subject><ispartof>Current obesity reports, 2015-12, Vol.4 (4), p.451-459</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-fe67690c026adb6a215862136da9c65af52da245c0a3b84e3ce550dd1baa0c093</citedby><cites>FETCH-LOGICAL-c457t-fe67690c026adb6a215862136da9c65af52da245c0a3b84e3ce550dd1baa0c093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13679-015-0177-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13679-015-0177-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26346394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arch, Jonathan R. S.</creatorcontrib><title>Horizons in the Pharmacotherapy of Obesity</title><title>Current obesity reports</title><addtitle>Curr Obes Rep</addtitle><addtitle>Curr Obes Rep</addtitle><description>Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT
2C
agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators’ caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.</description><subject>Adipose Tissue, Brown - drug effects</subject><subject>Adipose Tissue, Brown - metabolism</subject><subject>Anti-Obesity Agents - pharmacology</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Appetite Depressants - therapeutic use</subject><subject>Behavioral Therapy</subject><subject>Benzazepines - therapeutic use</subject><subject>Cardiology</subject><subject>Cinnamates - therapeutic use</subject><subject>Clinical Trials as Topic</subject><subject>Cyclohexanes - therapeutic use</subject><subject>Diabetes</subject><subject>Drug Approval</subject><subject>Drug Combinations</subject><subject>Endocrinology</subject><subject>Epoxy Compounds - therapeutic use</subject><subject>Europe</subject><subject>Humans</subject><subject>Lactones - therapeutic use</subject><subject>Liraglutide - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Metabolism (P Trayhurn</subject><subject>Molecular Targeted Therapy - trends</subject><subject>Obesity - drug therapy</subject><subject>Section Editor</subject><subject>Sesquiterpenes - therapeutic use</subject><subject>Thermogenesis - drug effects</subject><subject>Topical Collection on Metabolism</subject><subject>United States</subject><subject>Weight Loss - drug effects</subject><issn>2162-4968</issn><issn>2162-4968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF9LwzAUxYMobsx9AF-kjyJU8z_Nowx1wmA-6HO4TVPXsTYzaR_mpzejKj4ZCDmQcw73_hC6JPiWYKzuImFS6RwTka5SOT9BU0okzbmWxekfPUHzGLc4HYmJZPQcTahkXDLNp-hm6UPz6buYNV3Wb1z2soHQgvVJB9gfMl9n69LFpj9coLMadtHNv98Zent8eF0s89X66Xlxv8otF6rPayeV1NhiKqEqJVAiCknTsBVoKwXUglZAubAYWFlwx6wTAlcVKQFSSrMZuh5798F_DC72pm2idbsddM4P0RBFldaMFipZyWi1wccYXG32oWkhHAzB5kjJjJRMomSOlAxPmavv-qFsXfWb-GGSDHQ0xPTVvbtgtn4IXVr5n9Yvu_RwvA</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Arch, Jonathan R. S.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Horizons in the Pharmacotherapy of Obesity</title><author>Arch, Jonathan R. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-fe67690c026adb6a215862136da9c65af52da245c0a3b84e3ce550dd1baa0c093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adipose Tissue, Brown - drug effects</topic><topic>Adipose Tissue, Brown - metabolism</topic><topic>Anti-Obesity Agents - pharmacology</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Appetite Depressants - therapeutic use</topic><topic>Behavioral Therapy</topic><topic>Benzazepines - therapeutic use</topic><topic>Cardiology</topic><topic>Cinnamates - therapeutic use</topic><topic>Clinical Trials as Topic</topic><topic>Cyclohexanes - therapeutic use</topic><topic>Diabetes</topic><topic>Drug Approval</topic><topic>Drug Combinations</topic><topic>Endocrinology</topic><topic>Epoxy Compounds - therapeutic use</topic><topic>Europe</topic><topic>Humans</topic><topic>Lactones - therapeutic use</topic><topic>Liraglutide - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Metabolism (P Trayhurn</topic><topic>Molecular Targeted Therapy - trends</topic><topic>Obesity - drug therapy</topic><topic>Section Editor</topic><topic>Sesquiterpenes - therapeutic use</topic><topic>Thermogenesis - drug effects</topic><topic>Topical Collection on Metabolism</topic><topic>United States</topic><topic>Weight Loss - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arch, Jonathan R. S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current obesity reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arch, Jonathan R. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Horizons in the Pharmacotherapy of Obesity</atitle><jtitle>Current obesity reports</jtitle><stitle>Curr Obes Rep</stitle><addtitle>Curr Obes Rep</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>4</volume><issue>4</issue><spage>451</spage><epage>459</epage><pages>451-459</pages><issn>2162-4968</issn><eissn>2162-4968</eissn><abstract>Obesity drugs have had a chequered history. In the recent past, only the low efficacy, pancreatic lipase inhibitor orlistat was available worldwide and it was little used. The 5HT
2C
agonist, lorcaserin, and two combinations of old drugs have been approved in the United States but not in Europe. The diabetes drug liraglutide has been approved in both the US and Europe and seems likely to be most widely accepted. In view of regulators’ caution in approving obesity drugs, some (like beloranib) may initially be progressed for niche obesity markets. New drug targets have been identified in brown adipose tissue with the aim of not only activating thermogenesis but also increasing the capacity for thermogenesis in this tissue. Attempts are being made to match the efficacy of bariatric surgery by mimicking multiple gut hormones. Unapproved pharmacotherapies are tempting for some patients. Others remain optimistic about more conventional routes to pharmacotherapy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>26346394</pmid><doi>10.1007/s13679-015-0177-4</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2162-4968 |
| ispartof | Current obesity reports, 2015-12, Vol.4 (4), p.451-459 |
| issn | 2162-4968 2162-4968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1727993287 |
| source | MEDLINE; Springer Journals |
| subjects | Adipose Tissue, Brown - drug effects Adipose Tissue, Brown - metabolism Anti-Obesity Agents - pharmacology Anti-Obesity Agents - therapeutic use Appetite Depressants - therapeutic use Behavioral Therapy Benzazepines - therapeutic use Cardiology Cinnamates - therapeutic use Clinical Trials as Topic Cyclohexanes - therapeutic use Diabetes Drug Approval Drug Combinations Endocrinology Epoxy Compounds - therapeutic use Europe Humans Lactones - therapeutic use Liraglutide - therapeutic use Medicine Medicine & Public Health Metabolic Diseases Metabolism (P Trayhurn Molecular Targeted Therapy - trends Obesity - drug therapy Section Editor Sesquiterpenes - therapeutic use Thermogenesis - drug effects Topical Collection on Metabolism United States Weight Loss - drug effects |
| title | Horizons in the Pharmacotherapy of Obesity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T23%3A08%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Horizons%20in%20the%20Pharmacotherapy%20of%20Obesity&rft.jtitle=Current%20obesity%20reports&rft.au=Arch,%20Jonathan%20R.%20S.&rft.date=2015-12-01&rft.volume=4&rft.issue=4&rft.spage=451&rft.epage=459&rft.pages=451-459&rft.issn=2162-4968&rft.eissn=2162-4968&rft_id=info:doi/10.1007/s13679-015-0177-4&rft_dat=%3Cproquest_cross%3E1727993287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1727993287&rft_id=info:pmid/26346394&rfr_iscdi=true |